Roth Mkm Begins Coverage on Prenetics Global (NASDAQ:PRE)

Equities researchers at Roth Mkm started coverage on shares of Prenetics Global (NASDAQ:PRE) in a report issued on Wednesday, MarketBeat Ratings reports. The firm set a “buy” rating and a $36.00 price target on the stock. Roth Mkm’s price objective indicates a potential upside of 71.76% from the stock’s current price.

A number of other research analysts have also weighed in on the company. Wall Street Zen upgraded Prenetics Global from a “hold” rating to a “buy” rating in a report on Sunday, February 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Prenetics Global in a research report on Thursday, January 22nd. Finally, Cantor Fitzgerald boosted their price target on shares of Prenetics Global from $26.00 to $32.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Prenetics Global currently has an average rating of “Hold” and an average price target of $34.00.

Prenetics Global Trading Down 2.1%

Shares of Prenetics Global stock opened at $20.96 on Wednesday. Prenetics Global has a twelve month low of $3.09 and a twelve month high of $22.86. The firm has a market capitalization of $352.76 million, a PE ratio of -10.33 and a beta of 0.35. The firm’s 50-day moving average price is $17.10 and its 200 day moving average price is $13.47.

Prenetics Global (NASDAQ:PRE) last announced its earnings results on Monday, November 10th. The company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.14. The business had revenue of $23.56 million during the quarter, compared to analysts’ expectations of $26.00 million. Prenetics Global had a negative return on equity of 30.12% and a negative net margin of 60.70%. On average, sell-side analysts predict that Prenetics Global will post -3.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Jane Street Group LLC acquired a new stake in Prenetics Global during the fourth quarter worth about $1,302,000. T3 Companies LLC purchased a new stake in shares of Prenetics Global in the 4th quarter valued at approximately $170,000. Goldman Sachs Group Inc. acquired a new stake in shares of Prenetics Global during the 4th quarter worth approximately $665,000. Kingsview Wealth Management LLC purchased a new stake in shares of Prenetics Global during the 4th quarter valued at approximately $172,000. Finally, Stevens Capital Partners lifted its holdings in Prenetics Global by 4.7% in the fourth quarter. Stevens Capital Partners now owns 18,207 shares of the company’s stock valued at $287,000 after acquiring an additional 825 shares during the last quarter. Institutional investors and hedge funds own 25.01% of the company’s stock.

Prenetics Global Company Profile

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.